Eric Kelsic, Dyno Therapeutics CEO

Dyno's Er­ic Kel­sic fills the tank in his quest for bet­ter AAV with a group of big-name sup­port­ers on board

Ade­no-as­so­ci­at­ed virus­es (AAV) for gene ther­a­py have re­ceived a ton of scruti­ny through­out the field’s his­to­ry af­ter a smat­ter­ing of safe­ty scares and their lim­it­ed ther­a­peu­tic range. Hop­ing to crack the field wide open through a cap­sid de­sign rev­o­lu­tion, Er­ic Kel­sic and his team at Dyno have drummed up im­mense ex­cite­ment — and now a hefty war chest.

Dyno Ther­a­peu­tics has bagged a $100 mil­lion Se­ries A with back­ing from the likes of round leader An­dreessen Horowitz and new in­vestor Cas­din Cap­i­tal in its quest to use AI to de­sign bet­ter AAV cap­sids for gene ther­a­py, the com­pa­ny said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.